MX2015011362A - Metodo para el pronostico y tratamiento de metastasis de cancer. - Google Patents
Metodo para el pronostico y tratamiento de metastasis de cancer.Info
- Publication number
- MX2015011362A MX2015011362A MX2015011362A MX2015011362A MX2015011362A MX 2015011362 A MX2015011362 A MX 2015011362A MX 2015011362 A MX2015011362 A MX 2015011362A MX 2015011362 A MX2015011362 A MX 2015011362A MX 2015011362 A MX2015011362 A MX 2015011362A
- Authority
- MX
- Mexico
- Prior art keywords
- relates
- cancer
- metastasis
- bone metastasis
- gene
- Prior art date
Links
- 206010027476 Metastases Diseases 0.000 title abstract 8
- 230000009401 metastasis Effects 0.000 title abstract 8
- 206010028980 Neoplasm Diseases 0.000 title abstract 7
- 201000011510 cancer Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 238000004393 prognosis Methods 0.000 title abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 239000000523 sample Substances 0.000 abstract 3
- 102100039189 Transcription factor Maf Human genes 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000005945 translocation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801718P | 2013-03-15 | 2013-03-15 | |
| PCT/IB2014/001253 WO2014140933A2 (en) | 2013-03-15 | 2014-03-14 | Method for the prognosis and treatment of cancer metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015011362A true MX2015011362A (es) | 2015-12-16 |
Family
ID=51265712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011362A MX2015011362A (es) | 2013-03-15 | 2014-03-14 | Metodo para el pronostico y tratamiento de metastasis de cancer. |
| MX2020001156A MX2020001156A (es) | 2013-03-15 | 2015-09-02 | Metodo para el pronostico y tratamiento de metastasis de cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001156A MX2020001156A (es) | 2013-03-15 | 2015-09-02 | Metodo para el pronostico y tratamiento de metastasis de cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160032400A1 (enExample) |
| EP (1) | EP2971113B1 (enExample) |
| JP (1) | JP6577873B2 (enExample) |
| KR (1) | KR20150122731A (enExample) |
| CN (1) | CN105324491B (enExample) |
| AU (1) | AU2014229505B2 (enExample) |
| BR (1) | BR112015023783A2 (enExample) |
| CA (1) | CA2906394A1 (enExample) |
| MX (2) | MX2015011362A (enExample) |
| WO (1) | WO2014140933A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| AU2009253675A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| US8669057B2 (en) | 2009-05-07 | 2014-03-11 | Veracyte, Inc. | Methods and compositions for diagnosis of thyroid conditions |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| ES2562274T3 (es) | 2010-10-06 | 2016-03-03 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| EP2791359B1 (en) | 2011-12-13 | 2020-01-15 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) * | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| EP4219765B1 (en) | 2012-08-16 | 2024-12-18 | Veracyte SD, Inc. | Prostate cancer prognosis using biomarkers |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| HK1213946A1 (zh) | 2012-10-12 | 2016-07-15 | Inbiomotion S.L. | 用於使用c-maf对前列腺癌转移进行诊断、预後和治疗的方法 |
| EP3626308A1 (en) | 2013-03-14 | 2020-03-25 | Veracyte, Inc. | Methods for evaluating copd status |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| AU2014229563B2 (en) | 2013-03-15 | 2020-04-09 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of cancer metastasis |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| JP7356788B2 (ja) | 2014-11-05 | 2023-10-05 | ベラサイト インコーポレイテッド | 機械学習および高次元転写データを使用して経気管支生検における特発性肺線維症を診断するシステムおよび方法 |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| EP3417877A4 (en) * | 2016-02-18 | 2019-10-02 | Kyoto University | FOR INHIBITING THE GENETIC FUNCTION IN EXOSOM COMPLEX AND CANCER REPRODUCTION AND / OR METASTASE UPPRESSOR |
| CA3020329A1 (en) * | 2016-04-08 | 2017-10-12 | The Cleveland Clinic Foundation | Nanoparticles for drug delivery to treat bone disease |
| WO2017198609A1 (en) * | 2016-05-19 | 2017-11-23 | Probiocon Gmbh | Anti-cancer combination treatment |
| PL3458610T3 (pl) * | 2016-05-25 | 2021-11-22 | Inbiomotion S.L. | Leczenie raka piersi w oparciu o status c-MAF |
| AU2017296208A1 (en) * | 2016-07-12 | 2019-02-21 | The University Of North Carolina At Chapel Hill | Biomatrix scaffolds for use in diagnosing and modeling cancer |
| AU2017315425B2 (en) | 2016-08-24 | 2023-11-09 | The Regents Of The University Of Michigan | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| CA3050984A1 (en) | 2017-01-20 | 2018-07-26 | Decipher Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
| US11873532B2 (en) | 2017-03-09 | 2024-01-16 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| CA3062716A1 (en) | 2017-05-12 | 2018-11-15 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| JP2021504339A (ja) | 2017-11-22 | 2021-02-15 | インバイオモーション エセ．エレ． | ｃ−ＭＡＦの状態に基づく乳がんの治療的処置 |
| CN108084254A (zh) * | 2017-11-30 | 2018-05-29 | 天津市湖滨盘古基因科学发展有限公司 | 一种人的抗癌基因WWOXδ6-8突变蛋白及其应用 |
| WO2021185959A1 (en) * | 2020-03-19 | 2021-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Estrogen-related receptor alpha agonists for the treatment and the prognosis of bone metastases |
| CN115198013A (zh) * | 2021-04-14 | 2022-10-18 | 迪瑞药业(成都)有限公司 | 用以鉴别出适用精氨酸剥夺疗法的患者的方法与试剂盒 |
| EP4662491A2 (en) * | 2023-02-08 | 2025-12-17 | Iogenetics, LLC. | Expedited neoantigen vaccines |
| CN115919464B (zh) * | 2023-03-02 | 2023-06-23 | 四川爱麓智能科技有限公司 | 肿瘤定位方法、系统、装置及肿瘤发展预测方法 |
| CN119614707A (zh) * | 2025-01-13 | 2025-03-14 | 中山大学 | ERα生物标志物在ER+乳腺癌骨转移诊断、治疗和预后中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU580145B2 (en) | 1985-02-13 | 1989-01-05 | Scios Nova Inc. | Human metallothionein-ii promoter in mammalian expression system |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| IL126418A0 (en) | 1996-04-05 | 1999-05-09 | Salk Inst For Biological Studi | Hormone-mediated methods for modulating expression of exogenous genes and pharmaceutical compositions for modulating the same |
| JP2002509431A (ja) | 1996-12-23 | 2002-03-26 | イミュネックス・コーポレーション | ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である− |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| ES2215626T3 (es) | 1999-03-15 | 2004-10-16 | Axys Pharmaceuticals, Inc. | N-cianomethil amidas como inhibidores de proteasas. |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| CA2396257A1 (en) | 2000-01-06 | 2001-07-12 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | Novel compounds and compositions as protease inhibitors |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| MY143582A (en) | 2001-06-26 | 2011-05-31 | Amgent Fremont Inc | Antibodies to opgl |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| AU2003903540A0 (en) | 2003-07-09 | 2003-07-24 | Atdec Pty Ltd | Flat panel display wall mounting system |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| WO2005046731A1 (en) | 2003-10-17 | 2005-05-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| US20090048117A1 (en) | 2003-12-18 | 2009-02-19 | President And Fellows Of Harvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| WO2006012221A2 (en) | 2004-06-25 | 2006-02-02 | The Regents Of The University Of California | Target cell-specific short interfering rna and methods of use thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| WO2007069090A2 (en) | 2005-12-06 | 2007-06-21 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| RU2470665C2 (ru) * | 2006-01-05 | 2012-12-27 | Новартис Аг | Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| RU2481355C2 (ru) | 2007-05-24 | 2013-05-10 | Аблинкс Н.В. | Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей |
| WO2010000796A1 (en) * | 2008-07-02 | 2010-01-07 | Assistance Publique - Hôpitaux De Paris | A method for predicting clinical outcome of patients with non-small cell lung carcinoma |
| ES2562274T3 (es) * | 2010-10-06 | 2016-03-03 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama |
| WO2012064967A2 (en) * | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) * | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
-
2014
- 2014-03-14 CN CN201480015564.0A patent/CN105324491B/zh active Active
- 2014-03-14 JP JP2015562411A patent/JP6577873B2/ja active Active
- 2014-03-14 KR KR1020157026432A patent/KR20150122731A/ko not_active Ceased
- 2014-03-14 EP EP14747411.8A patent/EP2971113B1/en active Active
- 2014-03-14 CA CA2906394A patent/CA2906394A1/en active Pending
- 2014-03-14 BR BR112015023783A patent/BR112015023783A2/pt not_active Application Discontinuation
- 2014-03-14 MX MX2015011362A patent/MX2015011362A/es unknown
- 2014-03-14 WO PCT/IB2014/001253 patent/WO2014140933A2/en not_active Ceased
- 2014-03-14 AU AU2014229505A patent/AU2014229505B2/en active Active
- 2014-03-14 US US14/776,412 patent/US20160032400A1/en not_active Abandoned
-
2015
- 2015-09-02 MX MX2020001156A patent/MX2020001156A/es unknown
-
2021
- 2021-04-27 US US17/241,571 patent/US20210317534A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015023783A2 (pt) | 2017-10-24 |
| CN105324491B (zh) | 2021-10-26 |
| JP6577873B2 (ja) | 2019-09-18 |
| CN105324491A (zh) | 2016-02-10 |
| WO2014140933A8 (en) | 2020-10-01 |
| AU2014229505A1 (en) | 2015-09-03 |
| EP2971113B1 (en) | 2020-08-12 |
| WO2014140933A3 (en) | 2014-12-31 |
| JP2016516403A (ja) | 2016-06-09 |
| US20210317534A1 (en) | 2021-10-14 |
| MX2020001156A (es) | 2020-03-12 |
| US20160032400A1 (en) | 2016-02-04 |
| CA2906394A1 (en) | 2014-09-18 |
| WO2014140933A2 (en) | 2014-09-18 |
| EP2971113A2 (en) | 2016-01-20 |
| KR20150122731A (ko) | 2015-11-02 |
| AU2014229505B2 (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| WO2013153458A3 (en) | Method for the prognosis and treatment of cancer metastasis | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
| MX368513B (es) | Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón. | |
| MX2015004610A (es) | Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf. | |
| NZ599194A (en) | Methods to predict clinical outcome of cancer | |
| MX382266B (es) | Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama. | |
| Weller et al. | The role of tumour FoxP3 as prognostic marker in different subtypes of head and neck cancer | |
| MX2019007814A (es) | Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. | |
| NZ607282A (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| MX2014000292A (es) | Usos de inhibidores etiquetados hsp90. | |
| NZ705645A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
| JP2014144959A5 (enExample) | ||
| PH12019501942A1 (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| WO2017217807A3 (ko) | Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물 | |
| GB2523211A (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| EP4530631A3 (en) | New subpopulations of cancer associated fibroblasts as prognosis markers for immunotherapy treatments | |
| NZ610474A (en) | Methods to predict clinical outcome of cancer | |
| PL410186A1 (pl) | Sposób, zastosowanie i zestaw do wykrywania wysokiego ryzyka raka piersi o złym rokowaniu | |
| PL401271A1 (pl) | Sposób i zestaw do wykrywania agresywnego raka prostaty o złym rokowaniu | |
| UA82125U (ru) | Способ прогнозирования рефрактур у больных с ложными суставами | |
| UA96501U (uk) | Спосіб прогнозування зрощення перелому | |
| PL403515A1 (pl) | Sposób wykrywania in vitro agresywnych komórek nowotworowych o fenotypie macierzystym i/lub mezenchymalnym, zestaw do wykrywania oraz zastosowanie sposobu do wykrywania in vitro agresywnych komórek nowotworowych o fenotypie macierzystym i/lub mezenchymalnym do leczenia raka piersi |